Search Follow us


We are initiating coverage on CASI Pharmaceuticals, which is focused on leveraging regulatory synergies between the US and China to quickly bring products to market. The regulatory environment in China is rapidly evolving and is actively encouraging the entry of foreign drugs. CASI intends to leverage this with a portfolio of three proprietary oncology drugs (licensed from Spectrum) and 30 ANDAs (bought from Sandoz and Laurus Labs). We arrive at an initial valuation of $754m or $8.06 per share.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs